CCO Treatment Updates
Altering the Progression of Chronic Hepatitis B: Evidence and Urgency
Why Treat Hepatitis B Now? The Clinical View |
Module 1 of 3 |
|
Program Director: Emmet B. Keeffe, MD, MACP
- Emmet B. Keeffe, MD, MACP
|
|
|
Topics covered include:
- Introduction
- Treatment of Chronic Hepatitis B
- Course and Natural History
- Disease Progression
- Treatment of Chronic Hepatitis B
Learning Objectives
Upon completion of this activity, participants should be able to:
Explain the natural course of chronic hepatitis B infection Compare and contrast the available treatments for chronic hepatitis B Discuss the prevalence of chronic hepatitis B infection worldwide and the routes of transmission
|
Why Should We Treat Hepatitis B Now? The Economic View |
Module 2 of 3 |
|
Program Director: Emmet B. Keeffe, MD, MACP
|
|
Topics covered include:
- Burden of Hepatitis B Disease in the United States
- Addressing the Burden of Hepatitis B Disease
- Principles of Cost-Effectiveness Analyses
- The Cost-Effectiveness Plane
- Additional Considerations in Cost-Effectiveness Analysis: Quality of Life
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the burden of hepatitis B disease in the United States Review the cost-effectiveness studies of treatment for chronic hepatitis B, and their assumptions and limitations Explain the principles of cost-effectiveness analysis
|
What Can We Expect in the Future? |
Module 3 of 3 |
|
Program Director: Emmet B. Keeffe, MD, MACP
- Howard C. Thomas, BSc, PhD, FRCP, FRCPath, FmedSci
|
|
|
Topics covered include:
- Introduction: Stages of Infection
- Introduction: Immune Elimination Stage
- Immune Control and HBeAg- Viremic Stages
- Current Approaches to Treatment
- Short-Term (Circumscribed) Therapy
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe current optimal treatment for chronic hepatitis B Explain the stages of chronic hepatitis B infection Discuss future optimal treatment for chronic hepatitis B
|
Interactive Case Challenges
A 47-Year-Old Italian-American Man With Cirrhotic Hepatitis B
|
Program Director: Emmet B. Keeffe, MD, MACP
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
Assess the management of lamivudine-resistant graft disease. Describe recent data regarding the treatment of transplant recipients and the prevention of recurrent HBV disease. Review the treatment of decompensated liver disease.
|
A 28-Year-Old Physician With HBeAg-Positive Disease
|
Program Director: Emmet B. Keeffe, MD, MACP
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the approach to a patient who develops resistance to HBV therapy Discuss the considerations for individualizing therapy, taking into account renal function, pregnancy, and other concerns Evaluate the guidelines for instituting therapy in patients with HBV disease
|
A 43-Year-Old Man With Asymptomatic HBeAg-Negative Disease
|
Program Director: Emmet B. Keeffe, MD, MACP
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the indications and contraindications of agents used to treat chronic hepatitis B. Evaluate the guidelines for instituting therapy in patients with HBeAg-negative chronic hepatitis B. Discuss the challenges of long-term treatment of chronic hepatitis B. Review the approach to a patient who develops resistance to HBV therapy.
|
Corresponding PowerPoints for Each Module
Speakers' slides from the live symposium
These slide presentations are in Microsoft PowerPoint format. To view the slides in your browser, simply click the 'Download Slides' button. Mac Users: Slides will be downloaded to, and can be accessed from your desktop. You must be logged into the clinicaloptions.com site to view or save the slides.
Why Treat Hepatitis B Now? The Clinical View
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 1.48 MB
|
Why Should We Treat Hepatitis B Now? The Economic View
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 530 KB
|
What Can We Expect In the Future?
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 468 KB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|